KORU Medical Q4 Revenue Jumps 23%, Projects 15-22% Growth in 2026
Summary
KORU Medical Systems reported robust Q4 revenue growth of 23% year-over-year, with full-year revenue increasing by 22%. The company achieved positive adjusted EBITDA for both Q4 and the full year, signaling improved operational efficiency. Looking ahead, KORU Medical provided optimistic 2026 guidance, projecting net revenue growth between 15% and 22%, alongside expectations for positive adjusted EBITDA and cash flow. While Q4 net income was a loss of $500,000 and gross margin faced pressure from higher material costs and tariffs, the strong top-line growth and positive outlook for profitability and cash generation are material positives for the stock. Traders will be watching for continued execution on growth initiatives and effective cost management to sustain margin improvement.
At the time of this announcement, KRMD was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.7M. The 52-week trading range was $1.86 to $6.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.